Statins overprescribed for primary prevention

December 7, 2018, University of Zurich
Credit: CC0 Public Domain

Taking cholesterol-lowering drugs, or statins, as a preventive measure can reduce the risk of cardiovascular disease. A study by the University of Zurich now shows that this measure is recommended too often, as current guidelines fail to take into account the risks of side effects.

Even who don't suffer from a cardiovascular disease are prescribed cholesterol-lowering drugs, known as statins, if they meet certain risk criteria. However, for years the use of statins for primary prevention has been hotly debated among experts. "Ultimately, this measure helps to prevent heart attacks or strokes in only a few cases. But all people who take statins are at risk of experiencing the side effects," says Milo Puhan, professor of epidemiology and public health at the University of Zurich.

No systematic studies for guidelines

When deciding whether to prescribe statins to a patient, doctors use a number of risk factors such as cholesterol level, BMI and smoking to determine the likelihood of a person suffering a heart attack or stroke in the next 10 years. If this figure reaches or exceeds 10 percent, many medical guidelines recommend the use of statins; however, some guidelines put this number at 7.5 percent, whereas a Swiss association of general practitioners only suggests doing so from 20 percent.

If these guidelines, most of which are drawn up by cardiology organizations, are to be believed, more than one third of all people between the age of 40 and 75 would have to take statins as a – in other words, hundreds of millions of people around the world. According to Puhan, however, these guidelines were drawn up without properly taking into account the unwanted side effects, such as muscle pain, cataracts, liver defects or diabetes. "The thresholds set by experts aren't based on any systematic studies."

Weighing up benefits and harmful effects

Striking a good balance between the benefits and the is therefore one of the great challenges of developing improved guidelines for preventive use. This is why Prof. Milo Puhan and his team at the Epidemiology, Biostatistics and Prevention Institute of UZH have now for the first time carried out a comprehensive statistical modeling study.

The researchers systematically compiled all data from specialist literature that documents the benefits and side effects of the preventive use of statins. To include the view of patients in their model, they also performed a survey among healthy people about the significance of heart attacks, strokes and certain side effects.

Using this information, the scientists determined new thresholds for men and women across different age groups between 40 and 75. They also compared the benefits and unwanted side effects of four widely used statin preparations.

Recommendation given to too many people

"Our study shows that today statins are recommended far too often," says Puhan about the study's findings. According to his estimates, the newly set thresholds could cut the number of people who are given a recommendation to take statins by half.

The benefits of cholesterol-lowering drugs have been greatly exaggerated particularly when it comes to senior citizens: For the 70 to 75 age group, the study's model put the threshold at approx. 21 percent – in other words, the benefits of statins outweigh the harm from potential side effects of statins only if there's a 21 percent risk or higher that a person will suffer a or a stroke in the next 10 years. For men and women aged 40 to 45, the threshold is slightly lower, at 14 percent and 17 percent respectively. The researchers also noted that two of the four examined statin preparations, atorvastatin and rosuvastatin, had a significantly better balance of benefits and harms than the other two (simvastatin und pravastatin).

Considering the study's findings, Puhan recommends that all people concerned should discuss their individual risk for cardiovascular disease as well as possible with their doctors before deciding whether to take statins as a preventive measure.

Explore further: Evidence does not support statin use for conditions other than heart disease

More information: Henock G. Yebyo et al. Finding the Balance Between Benefits and Harms When Using Statins for Primary Prevention of Cardiovascular Disease, Annals of Internal Medicine (2018). DOI: 10.7326/M18-1279

Related Stories

Evidence does not support statin use for conditions other than heart disease

October 9, 2018
Despite studies suggesting benefits for conditions beyond cardiovascular disease (CVD), the evidence does not support revising current statin prescribing guidelines. Findings from an evidence review and meta-analysis are ...

Cholesterol lowering drugs cut risk of a first heart attack or stroke

November 14, 2016
Cholesterol-lowering drugs help prevent heart attacks and strokes in adults with cardiovascular risk factors such as high cholesterol, high blood pressure, diabetes and smoking, but have not yet had a heart attack or stroke, ...

Statins save lives of people with high levels of LDL cholesterol

April 17, 2018
Cholesterol-lowering drugs are more likely to save thousands of additional lives when used in people with higher levels of LDL cholesterol, or "bad" cholesterol, according to a new study from the University of Iowa, published ...

New advice on who qualifies for cholesterol-lowering statins

December 22, 2015
Considering a cholesterol-lowering statin to prevent a heart attack? Deciding who's a good candidate requires calculating more than a simple cholesterol level.

Statins don't cause muscle pain: study

May 3, 2017
Cholesterol-lowering statin drugs may have been wrongly blamed for muscle pain and weakness, said a study Wednesday that pointed the finger at a psychological phenomenon called the "nocebo" effect.

Genetic testing for statin therapy not cost-effective

June 4, 2018
Current United States Preventive Service Task Force (USPSTF) guidelines call for screening all Americans between the ages of 40 and 75 years to determine eligibility for statins, a class of cholesterol-lowering medications. ...

Recommended for you

New understanding of mysterious 'hereditary swelling'

December 12, 2018
For the first time ever, biomedical researchers from Aarhus University, Denmark, report cellular defects that lead to a rare disease, hereditary angioedema (HAE), in which patients experience recurrent episodes of swelling ...

Research team traces pathway to cardioprotection in post-ischemic heart failure

December 11, 2018
During an ischemic attack, the heart is temporarily robbed of its blood supply. The aftermath is devastating: reduced heart contractility, heart cell death, and heart failure. Contributing to these detrimental changes is ...

Macrophage cells key to helping heart repair—and potentially regenerate, new study finds

December 11, 2018
Scientists at the Peter Munk Cardiac Centre have identified the type of cell key to helping the heart repair and potentially regenerate following a heart attack.

Study reveals new link between atrial fibrillation and mutations in heart disease gene

December 11, 2018
Atrial fibrillation (Afib), a heart condition that causes a rapid, irregular heartbeat that increases a person's risk of stroke and heart failure, is fairly common among older adults. However, its early onset form is relatively ...

Researchers have found that incidence of heart failure was around two-fold higher in people with diabetes

December 11, 2018
Researchers have found that incidence of heart failure was around two-fold higher in people with diabetes.

Workplace exposure to pesticides and metals linked to heightened heart disease risk

December 11, 2018
Workplace exposure to metals and pesticides is linked to a heightened risk of heart disease in Hispanic and Latino workers, reveals research published online in the journal Heart.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.